Company Analysis MEDNAX, Inc.
1. Summary
Advantages
- The stock's return over the last year (43.41%) is higher than the sector average (-13.41%).
- Current debt level 29.17% is below 100% and has decreased over 5 years from 43.86%.
- The company's current efficiency (ROE=-7.11%) is higher than the sector average (ROE=-80.87%)
Disadvantages
- Price (15.21 $) is higher than fair price (12.94 $)
- Dividends (0%) are below the sector average (1.28%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| MEDNAX, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.8% | -12% | -1.5% |
| 90 days | 20.7% | -19.6% | -0.4% |
| 1 year | 43.4% | -13.4% | 22.5% |
MD vs Sector: MEDNAX, Inc. has outperformed the "Healthcare" sector by 56.82% over the past year.
MD vs Market: MEDNAX, Inc. has outperformed the market by 20.87% over the past year.
Stable price: MD is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MD with weekly volatility of 0.8348% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (15.21 $) is higher than the fair price (12.94 $).
Price is higher than fair: The current price (15.21 $) is 14.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (18.87) is lower than that of the sector as a whole (57.85).
P/E vs Market: The company's P/E (18.87) is lower than that of the market as a whole (47.37).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.9236) is lower than that of the sector as a whole (9.39).
P/BV vs Market: The company's P/BV (0.9236) is lower than that of the market as a whole (22.69).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.3932) is lower than that of the sector as a whole (4.05).
P/S vs Market: The company's P/S indicator (0.3932) is lower than that of the market as a whole (15.16).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (7.2) is lower than that of the sector as a whole (17.49).
EV/Ebitda vs Market: The company's EV/Ebitda (7.2) is lower than that of the market as a whole (17.77).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 105.85% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (105.85%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-69.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-7.11%) is higher than that of the sector as a whole (-80.87%).
ROE vs Market: The company's ROE (-7.11%) is lower than that of the market as a whole (17.14%).
5.5. ROA
ROA vs Sector: The company's ROA (-2.72%) is lower than that of the sector as a whole (6.7%).
ROA vs Market: The company's ROA (-2.72%) is lower than that of the market as a whole (6.51%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.87%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (7.87%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.28%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 13.11.2024 | ORDAN MARK S Director |
Purchase | 15.5 | 427 800 | 27 600 |
| 30.08.2024 | Swift James D Officer |
Purchase | 10.79 | 119 769 | 11 100 |
| 11.01.2022 | MEDEL ROGER MD Director |
Sale | 26.58 | 1 066 040 | 40 107 |
| 10.01.2022 | MEDEL ROGER MD Director |
Sale | 26.44 | 1 583 570 | 59 893 |
| 04.01.2022 | MEDEL ROGER MD Director |
Sale | 27.43 | 2 396 310 | 87 361 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
